| Latest | F'cast | |
|---|---|---|
| Div Yield | 3.2% | 3.1% |
| Div Cover | 2.4 | 2.6 |
| Op Mrgn | 11.9% | 13.8% |
| ROCE | 26.6% |
| Latest | F'cast | |
|---|---|---|
| P/E | 13.2 | 12.2 |
| PEG | 1.9 | 1.5 |
| Pr/Revenue | 1.3 | 1.3 |
| Pr/Book | 2.2 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 5.8% | 3.9% |
| PBT | 21.4% | 49.3% |
| EPS | 7.1% | 7.9% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 28-Apr-07 | 126.48 | 15.65 | 44.30p | 16.5 | 0.9 | +18% | 19.10p | 2.6% |
| 03-May-08 | 132.95 | 4.18 | 44.70p | 13.8 | 13.8 | +1% | 19.10p | 3.1% |
| 30-Apr-09 | 129.90 | 11.96 | 45.10p | 8.6 | 8.6 | +1% | 19.10p | 4.9% |
| 30-Apr-10 | 125.13 | 10.46 | 42.50p | 8.6 | n/a | -6% | 19.10p | 5.2% |
| 30-Apr-11 | 132.37 | 12.70 | 45.50p | 12.7 | 1.8 | +7% | 19.10p | 3.3% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Apr-12 | 137.48 | 18.96 | 49.11p | 12.2 | 1.5 | +8% | 19.10p | 3.1% |
| 30-Apr-13 | 144.78 | 20.42 | 52.33p | 11.5 | 1.8 | +7% | 19.10p | 3.1% |
| 30-Apr-14 | 150.37 | 22.50 | 57.55p | 10.4 | 1.0 | +10% | 19.10p | 3.1% |
Copyright © 2012 FactSet Research Systems Inc. All rights reserved.
| Total Voting Rights | 01-May-2012 | 10:21 | RNS |
| FDA Approval Proprietary Integrated Dose Counter | 30-Apr-2012 | 07:00 | RNS |
| Holding(s) in Company | 20-Apr-2012 | 10:54 | RNS |
| Consort Medical gets US thumbs up | 30-Apr-2012 | ShareCast |
| Margins squeezed in Dechra's Services business | 21-Feb-2012 | ShareCast |
| Whitbread chief keeps the faith | 13-Dec-2011 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 600.00p |
| Change Today | 5.00p |
| % Change | 0.84 % |
| 52 Week High | 668.00p |
| 52 Week Low | 498.00p |
| Volume | 25,378 |
| Shares Issued | 29.01m |
| Market Cap | £174.07m |
| Beta | 0.19 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 6 |
| Buy | 1 |
| Neutral | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 9 |

| Latest | Previous | |
|---|---|---|
| Interim | Final | |
| Ex-Div | 18-Jan-12 | 21-Sep-11 |
| Paid | 17-Feb-12 | 28-Oct-11 |
| Amount | 7.00p | 12.10p |
| Time | Volume / Share Price |
| 16:35 | 428 @ 600.00p |
| 16:22 | 74 @ 599.00p |
| 16:22 | 1,500 @ 599.00p |
| 16:22 | 1,000 @ 600.00p |
| 16:22 | 172 @ 600.50p |
| Chair | Peter Fellner |
| CEO | Jonathan Glenn |
You are here: research